Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Sponsor
AVM Biotechnology Inc (Industry)
Overall Status
Available
CT.gov ID
NCT05974410
Collaborator
(none)
Study Details
Study Description
Brief Summary
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2023, 22 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- AVM Biotechnology Inc
Investigators
- Study Director: Edward Loniewski, D.O., AVM Biotechnology Inc
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
AVM Biotechnology Inc
ClinicalTrials.gov Identifier:
NCT05974410
Other Study ID Numbers:
- AVM0703-EAP
First Posted:
Aug 3, 2023
Last Update Posted:
Aug 3, 2023
Last Verified:
Jul 1, 2023
Additional relevant MeSH terms: